Tetz, GeorgeCynamon, MichaelHendricks, Gregory M.Vikina, DariaTetz, Victor2022-08-232022-08-232017-07-012017-06-19Int J Antimicrob Agents. 2017 Jul;50(1):47-54. 10.1016/j.ijantimicag.2017.02.011. Epub 2017 Apr 27. <a href="https://doi.org/10.1016/j.ijantimicag.2017.02.011">Link to article on publisher's site</a>0924-8579 (Linking)10.1016/j.ijantimicag.2017.02.01128457835https://hdl.handle.net/20.500.14038/48212There is an urgent need for new antifungal compounds to treat various types of fungal infections, including pulmonary infections. This study was designed to investigate the potency of a novel compound (Mul-1867) against Candida spp. and Aspergillus spp. isolated from patients with fungal pneumonia, cystic fibrosis and chronic obstructive pulmonary disease. Mul-1867 was highly effective against susceptible control strains as well as resistant clinical isolates, with minimum fungicidal concentrations (MFCs) varying from 0.06 microg/mL to 0.5 microg/mL. It was also highly effective against pre-formed 48-h-old biofilms formed by yeasts and moulds. The half-minimal biofilm eradication concentration (MBEC50) was equal to the MFC. The minimum biofilm eradication concentration to eliminate 90% of biofilms (MBEC90) varied from 1 x to 4 x MFC. Scanning electron microscopy revealed morphological changes accompanied by the release of intracellular material from the fungal cells following exposure to Mul-1867. Furthermore, an increased concentration of nucleic acids was found in the medium after 5 min and 20 min of Mul-1867 treatment, indicating leakage of cytoplasmic contents. Overall, these data indicate that Mul-1867 may be a promising inhaled antifungal agent for the treatment and prevention of fungal respiratory infections.en-USBiofilmCystic fibrosisFungiImmunocompromisedPulmonary infectionResistantBacterial Infections and MycosesChemicals and DrugsRadiologyRespiratory Tract DiseasesJournal Articlehttps://escholarship.umassmed.edu/radiology_pubs/32810320240radiology_pubs/328